192 related articles for article (PubMed ID: 27711083)
1. RADVAN: a randomised phase 2 trial of WBRT plus vandetanib for melanoma brain metastases - results and lessons learnt.
Gupta A; Roberts C; Tysoe F; Goff M; Nobes J; Lester J; Marshall E; Corner C; Wolstenholme V; Kelly C; Wise A; Collins L; Love S; Woodward M; Salisbury A; Middleton MR
Br J Cancer; 2016 Nov; 115(10):1193-1200. PubMed ID: 27711083
[TBL] [Abstract][Full Text] [Related]
2. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.
Leboulleux S; Bastholt L; Krause T; de la Fouchardiere C; Tennvall J; Awada A; Gómez JM; Bonichon F; Leenhardt L; Soufflet C; Licour M; Schlumberger MJ
Lancet Oncol; 2012 Sep; 13(9):897-905. PubMed ID: 22898678
[TBL] [Abstract][Full Text] [Related]
3. Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases.
Lee SM; Lewanski CR; Counsell N; Ottensmeier C; Bates A; Patel N; Wadsworth C; Ngai Y; Hackshaw A; Faivre-Finn C
J Natl Cancer Inst; 2014 Jul; 106(7):. PubMed ID: 25031274
[TBL] [Abstract][Full Text] [Related]
4. Surgery versus stereotactic radiotherapy for people with single or solitary brain metastasis.
Fuentes R; Osorio D; Expósito Hernandez J; Simancas-Racines D; Martinez-Zapata MJ; Bonfill Cosp X
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012086. PubMed ID: 30125049
[TBL] [Abstract][Full Text] [Related]
5. Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases.
Tsao MN; Lloyd N; Wong RK; Chow E; Rakovitch E; Laperriere N; Xu W; Sahgal A
Cochrane Database Syst Rev; 2012 Apr; 2012(4):CD003869. PubMed ID: 22513917
[TBL] [Abstract][Full Text] [Related]
6. Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR).
Lee JS; Hirsh V; Park K; Qin S; Blajman CR; Perng RP; Chen YM; Emerson L; Langmuir P; Manegold C
J Clin Oncol; 2012 Apr; 30(10):1114-21. PubMed ID: 22370318
[TBL] [Abstract][Full Text] [Related]
7. Whole brain radiotherapy after local treatment of brain metastases in melanoma patients--a randomised phase III trial.
Fogarty G; Morton RL; Vardy J; Nowak AK; Mandel C; Forder PM; Hong A; Hruby G; Burmeister B; Shivalingam B; Dhillon H; Thompson JF
BMC Cancer; 2011 Apr; 11():142. PubMed ID: 21496312
[TBL] [Abstract][Full Text] [Related]
8. Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer.
Koehler VF; Adam P; Frank-Raue K; Raue F; Berg E; Hoster E; Allelein S; Schott M; Kroiss M; Spitzweg C
Thyroid; 2021 Mar; 31(3):459-469. PubMed ID: 32781914
[No Abstract] [Full Text] [Related]
9. Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial.
Yang JJ; Zhou C; Huang Y; Feng J; Lu S; Song Y; Huang C; Wu G; Zhang L; Cheng Y; Hu C; Chen G; Zhang L; Liu X; Yan HH; Tan FL; Zhong W; Wu YL
Lancet Respir Med; 2017 Sep; 5(9):707-716. PubMed ID: 28734822
[TBL] [Abstract][Full Text] [Related]
10. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer.
Natale RB; Thongprasert S; Greco FA; Thomas M; Tsai CM; Sunpaweravong P; Ferry D; Mulatero C; Whorf R; Thompson J; Barlesi F; Langmuir P; Gogov S; Rowbottom JA; Goss GD
J Clin Oncol; 2011 Mar; 29(8):1059-66. PubMed ID: 21282542
[TBL] [Abstract][Full Text] [Related]
11. Single institutional outcomes of whole brain radiotherapy for metastatic melanoma brain metastases.
Jiang C; Kleber TJ; Switchenko JM; Khan MK
Radiat Oncol; 2021 Feb; 16(1):31. PubMed ID: 33557890
[TBL] [Abstract][Full Text] [Related]
12. A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320.
Sperduto PW; Wang M; Robins HI; Schell MC; Werner-Wasik M; Komaki R; Souhami L; Buyyounouski MK; Khuntia D; Demas W; Shah SA; Nedzi LA; Perry G; Suh JH; Mehta MP
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1312-8. PubMed ID: 23391814
[TBL] [Abstract][Full Text] [Related]
13. Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases.
Tsao MN; Xu W; Wong RK; Lloyd N; Laperriere N; Sahgal A; Rakovitch E; Chow E
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD003869. PubMed ID: 29365347
[TBL] [Abstract][Full Text] [Related]
14. Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial.
Mulvenna P; Nankivell M; Barton R; Faivre-Finn C; Wilson P; McColl E; Moore B; Brisbane I; Ardron D; Holt T; Morgan S; Lee C; Waite K; Bayman N; Pugh C; Sydes B; Stephens R; Parmar MK; Langley RE
Lancet; 2016 Oct; 388(10055):2004-2014. PubMed ID: 27604504
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab and gefitinib enhanced whole-brain radiation therapy for brain metastases due to non-small-cell lung cancer.
Yang RF; Yu B; Zhang RQ; Wang XH; Li C; Wang P; Zhang Y; Han B; Gao XX; Zhang L; Jiang ZM
Braz J Med Biol Res; 2017 Nov; 51(1):e6073. PubMed ID: 29185589
[TBL] [Abstract][Full Text] [Related]
16. A Randomized Controlled Open-Label Pilot Study of Simvastatin Addition to Whole-Brain Radiation Therapy in Patients With Brain Metastases.
El-Hamamsy M; Elwakil H; Saad AS; Shawki MA
Oncol Res; 2016 Oct; 24(6):521-528. PubMed ID: 28281972
[TBL] [Abstract][Full Text] [Related]
17. Veliparib in combination with whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer: results of a randomized, global, placebo-controlled study.
Chabot P; Hsia TC; Ryu JS; Gorbunova V; Belda-Iniesta C; Ball D; Kio E; Mehta M; Papp K; Qin Q; Qian J; Holen KD; Giranda V; Suh JH
J Neurooncol; 2017 Jan; 131(1):105-115. PubMed ID: 27655223
[TBL] [Abstract][Full Text] [Related]
18. Vandetanib in patients with inoperable hepatocellular carcinoma: a phase II, randomized, double-blind, placebo-controlled study.
Hsu C; Yang TS; Huo TI; Hsieh RK; Yu CW; Hwang WS; Hsieh TY; Huang WT; Chao Y; Meng R; Cheng AL
J Hepatol; 2012 May; 56(5):1097-1103. PubMed ID: 22245891
[TBL] [Abstract][Full Text] [Related]
19. Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer.
Choueiri TK; Ross RW; Jacobus S; Vaishampayan U; Yu EY; Quinn DI; Hahn NM; Hutson TE; Sonpavde G; Morrissey SC; Buckle GC; Kim WY; Petrylak DP; Ryan CW; Eisenberger MA; Mortazavi A; Bubley GJ; Taplin ME; Rosenberg JE; Kantoff PW
J Clin Oncol; 2012 Feb; 30(5):507-12. PubMed ID: 22184381
[TBL] [Abstract][Full Text] [Related]
20. SAFETY AND TOLERABILITY OF VANDETANIB IN JAPANESE PATIENTS WITH MEDULLARY THYROID CANCER: A PHASE I/II OPEN-LABEL STUDY.
Uchino K; Komoda M; Tomomatsu J; Okamoto T; Horiuchi K; Tsuji A; Ito Y; Todo T; Rito K; Takahashi S
Endocr Pract; 2017 Feb; 23(2):149-156. PubMed ID: 27819766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]